International Rett Syndrome Foundation Translational Research Program

International Rett Syndrome Foundation Translational Research Program Cycle 1 Letter of Intent due: February 1, 2013 IRSF announces the availability of HeART (Help Accelerate RTT Therapeutics) and ANGEL (Advanced Neurotherapeutic Grant of Excellence) grant awards to promote the development and testing of therapeutics to treat and reverse Rett syndrome (RTT) and its symptoms. These award mechanisms seek to facilitate the development and testing of novel therapeutics targeting the underlying pathology of the disorder, thereby leading to an amelioration of symptoms or ultimately a pharmacological reversal of RTT. Through these awards, IRSF seeks to foster academic and public-private partnerships and further facilitate drug discovery, development and testing. IRSF encourages novel research programs that broadly encompass the following areas of unmet need: Design, synthesis and testing of potential disease modifying therapeutics to treat or reverse RTT Testing of existing therapeutics both in vitro and in vivo to repurpose their use in RTT Development and/or validation of in vitro and in vivo models of RTT for therapeutic testing Development and/or validation of novel biomarkers for objective clinical trials outcome measures Testing of IND-ready therapeutics in pilot clinical trials IRSF encourages investigators to utilize the newly available IRSF SMART Library of compounds in their proposed studies. HeART (Help Accelerate RTT Therapeutics) ...
Source: ScanGrants feed - Category: Research Authors: Source Type: funding